arGentis Pharmaceuticals, LLC – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "arGentis Pharmaceuticals, LLC - Product Pipeline Review - 2012" provides data on the arGentis Pharmaceuticals, LLC's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, arGentis Pharmaceuticals, LLC's corporate website, SEC filings, investor presentations and featured press releases, both from arGentis Pharmaceuticals, LLC and industry-specific third party sources, put together by our team.
Scope
- arGentis Pharmaceuticals, LLC - Brief arGentis Pharmaceuticals, LLC overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of arGentis Pharmaceuticals, LLC human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of arGentis Pharmaceuticals, LLC with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the arGentis Pharmaceuticals, LLC's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate arGentis Pharmaceuticals, LLC's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of arGentis Pharmaceuticals, LLC in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the arGentis Pharmaceuticals, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with arGentis Pharmaceuticals, LLC.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of arGentis Pharmaceuticals, LLC and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
arGentis Pharmaceuticals, LLC Snapshot
arGentis Pharmaceuticals, LLC Overview
Key Information
Key Facts
arGentis Pharmaceuticals, LLC – Research and Development Overview
Key Therapeutic Areas
arGentis Pharmaceuticals, LLC – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
arGentis Pharmaceuticals, LLC – Pipeline Products Glance
arGentis Pharmaceuticals, LLC Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
arGentis Pharmaceuticals, LLC – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
arGentis Pharmaceuticals, LLC – Drug Profiles
ARG-103
Product Description
Mechanism of Action
R&D Progress
ARG-301
Product Description
Mechanism of Action
R&D Progress
testosterone
Product Description
Mechanism of Action
R&D Progress
VeriCol
Product Description
Mechanism of Action
R&D Progress
arGentis Pharmaceuticals, LLC – Pipeline Products by Route of Administration
arGentis Pharmaceuticals, LLC - Dormant Projects
arGentis Pharmaceuticals, LLC – Locations And Subsidiaries
Head Office
Financial Deals Landscape
arGentis Pharmaceuticals, LLC, Deals Summary
arGentis Pharmaceuticals, LLC, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
arGentis Pharma Secures Investment From Innova Memphis
ArGentis Pharma Raises $1 Million In Venture Financing
Licensing Agreements
arGentis Pharma Expands Licensing Agreement With Southern College of Optometry
arGentis Pharma Expands Its Licensing Agreement With Southern College of Optometry
arGentis Pharma Enters Into Licensing Agreement With Southern College of Optometry
arGentis Enters Into Licensing Agreement With UTHSC And VAMC
arGentis Pharma Enters Into Licensing Agreement With University of Tennessee Research Foundation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
arGentis Pharmaceuticals, LLC, Key Information
arGentis Pharmaceuticals, LLC, Key Facts
arGentis Pharmaceuticals, LLC – Pipeline by Indication, 2012
arGentis Pharmaceuticals, LLC – Pipeline by Stage of Development, 2012
arGentis Pharmaceuticals, LLC – Monotherapy Products in Pipeline, 2012
arGentis Pharmaceuticals, LLC – Phase I, 2012
arGentis Pharmaceuticals, LLC – Pre-Clinical, 2012
arGentis Pharmaceuticals, LLC – Pipeline By Route of Administration, 2012
arGentis Pharmaceuticals, LLC - Dormant Developmental Projects,2012
arGentis Pharmaceuticals, LLC, Deals Summary
arGentis Pharma Secures Investment From Innova Memphis
ArGentis Pharma Raises $1 Million In Venture Financing
arGentis Pharma Expands Licensing Agreement With Southern College of Optometry
arGentis Pharma Expands Its Licensing Agreement With Southern College of Optometry
arGentis Pharma Enters Into Licensing Agreement With Southern College of Optometry
arGentis Enters Into Licensing Agreement With UTHSC And VAMC
arGentis Pharma Enters Into Licensing Agreement With University of Tennessee Research Foundation
List of Figures
arGentis Pharmaceuticals, LLC – Pipeline by Indication, 2012
arGentis Pharmaceuticals, LLC – Pipeline by Stage of Development, 2012
arGentis Pharmaceuticals, LLC – Monotherapy Products in Pipeline, 2012
arGentis Pharmaceuticals, LLC – Pipeline By Route of Administration, 2012 16